Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges: 2010-2025

Historic Amortization of Deferred Charges for Ligand Pharmaceuticals (LGND) over the last 13 years, with Sep 2025 value amounting to $447,000.

  • Ligand Pharmaceuticals' Amortization of Deferred Charges rose 233.58% to $447,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $880,000, marking a year-over-year increase of 122.78%. This contributed to the annual value of $486,000 for FY2024, which is 102.50% up from last year.
  • Ligand Pharmaceuticals' Amortization of Deferred Charges amounted to $447,000 in Q3 2025, which was up 257.60% from $125,000 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $4.9 million in Q1 2021 and a low of $64,000 during Q2 2023.
  • Its 3-year average for Amortization of Deferred Charges is $143,400, with a median of $110,500 in 2024.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Amortization of Deferred Charges plummeted by 97.52% in 2022 and then surged by 233.58% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $3.8 million in 2021, then tumbled by 97.52% to $95,000 in 2022, then decreased by 14.74% to $81,000 in 2023, then spiked by 112.35% to $172,000 in 2024, then skyrocketed by 233.58% to $447,000 in 2025.
  • Its Amortization of Deferred Charges stands at $447,000 for Q3 2025, versus $125,000 for Q2 2025 and $136,000 for Q1 2025.